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Abstract: Medically important cases of snakebite in Europe are predominately caused by 
European vipers of the genus Vipera. The mainstay of snakebite therapy is polyclonal 
antibody therapy, referred to as antivenom. Here we investigate the capability of the 
monospecific V. berus antivenom, ViperaTAb
®
, to cross-react with, and neutralise lethality 
induced by, a variety of European vipers. Using ELISA and immunoblotting, we find that 
ViperaTAb
®
 antibodies recognise and bind to the majority of toxic components found in 
the venoms of the Vipera species tested at comparably high levels to those observed with 
V. berus. Using in vivo pre-clinical efficacy studies, we demonstrate that ViperaTAb
®
 
effectively neutralises lethality induced by V. berus, V. aspis, V. ammodytes and V. latastei 
venoms and at much higher levels than those outlined by regulatory pharmacopoeial 
guidelines. Notably, venom neutralisation was found to be superior to (V. berus, V. aspis 
and V. latastei), or as equally effective as (V. ammodytes), the monospecific V. ammodytes 
―Zagreb antivenom‖, which has long been successfully used for treating European snake 
envenomings. This study suggests that ViperaTAb
®
 may be a valuable therapeutic product 
for treating snakebite by a variety of European vipers found throughout the continent. 
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1. Introduction 
All of the medically-important venomous snakes found in Europe are members of the family 
Viperidae (vipers), with the vast majority belonging to the genus Vipera. These snakes are broadly 
referred to as the ―European vipers‖ and include species such as V. berus from north Europe (including 
the UK, Nordic countries, the Netherlands, Poland and Germany), V. aspis from south and west 
Europe (including France and Italy), V. ammodytes from south and east Europe (including northeast 
Italy and the Balkans), V. latastei from south-west Europe (Portugal and Spain) and V. ursinii  
from central and eastern Europe (parts of France, Italy and the Balkans). In addition, two  
medically-important species from different genera, Macrovipera lebetina and Montivipera xanthina 
are both found in parts of south-eastern Europe, such as Turkey and Greece. These two species are 
closely related to the Vipera European vipers and until recently were classified as members of the 
same genus. 
Snakebite is classified by the World Health Organisation as a neglected tropical disease, with 
perhaps as many as 94,000 people dying each year worldwide as the result of snake envenomings [1]. 
The majority of these cases occur in the tropical and sub-tropical regions of the world, inhabited by the 
rural poor [1,2]. However, recent estimates suggest that ~8,000 cases of snakebite occur each year in 
Europe, with 1,000 of these resulting in systemic envenoming and approximately four deaths [3]. 
Systemic envenoming by European vipers can cause severe pathology in humans, although fatalities 
are rare. The clinical manifestations can be variable and diverse in nature and this variability is 
observed across bites by different members of this genus (cf. [4–6]). Symptoms can include pain at  
the bite site, progressive local swelling, vomiting, tachycardia, hypotension, acute renal failure, 
haemorrhage, angio-oedema, pulmonary oedema, cardiac arrest, and on rare occasions, neurotoxicity 
and hypertension [4–15]. 
The mainstay of snakebite therapy consists of polyclonal antibodies made by hyper-immunising 
horses or sheep with relevant snake venom(s) and is termed antivenom. ViperaTAb
®
 is a monospecific 
ovine antivenom raised against the venom of V. berus and is manufactured by MicroPharm Limited in 
the United Kingdom. The antivenom is made from hyper-immunised sheep serum and consists of 
ovine Fab fragments which are cleaved from intact IgG molecules during manufacturing [16]. 
Subsequently, the Fab fragments are affinity purified using column chromatography, meaning that all 
of the antibodies present in ViperaTAb
®
 are specific to snake venom toxins. This is unlike a number of 
other snake antivenoms, where perhaps only 10% of the immunoglobulins present are actually specific 
to venom immunogens [17] due to the animals being immunised generating antibodies to other 
environmental antigens they are exposed to. ViperaTAb
®
 is formulated at a concentration of  
25 mg/mL with a fill volume of 4 mL, resulting in 100 mg of specific Fab being delivered per  
therapeutic dose. 
Fab antibodies offer a number of advantages over IgG and F(ab')2 antivenoms, most notably a 
pharmacokinetic advantage in that the molecular weight of Fab (~50 kDa) is much smaller than IgG 
(~150 kDa) and F(ab')2 (~100 kDa) and therefore permits a larger volume of distribution [18,19]. 
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Considering the size of Fab is comparable to many of the toxic constituents of snake venoms (typically 
up to ~75 kDa in size), it is advantageous to have antibodies that are likely to have a similar volume of 
distribution to the toxins that they are targeting, as this may enable the earlier neutralisation of venom. 
However, these advantages come at some cost—whilst the faster elimination of Fab is likely to reduce 
the risk of longer-term adverse effects (i.e., serum sickness), careful clinical management is essential 
because of the risk of recrudescence if venom continues to diffuse out from the bite site after the  
Fab has been cleared. Nonetheless, due to the relatively small amounts of venom injected by V. berus 
during envenomings (~5–10 mg), recrudescence has not proven to be a major issue with the 
management of European viper snakebite, unlike observed elsewhere [20]. Indeed, a clinical trial 
undertaken with 231 patients in Scandinavia revealed that, of those envenomed victims that received 
antivenom, only 13% required a second vial of ViperaTAb
®
 during treatment [5]. Most importantly, 
ViperaTAb
®
 has been demonstrated to be highly efficacious and safe in human patients suffering 
systemic envenoming by V. berus in Scandinavia and this antivenom has been successfully used in the 
region for more than two decades [5,21]. 
Because of the inherent compositional variability of the toxic components found in the venom of 
different snake species [22–24], predicting the cross-neutralisation of heterologous venoms by 
monospecific antivenoms is exceedingly problematic [17,25,26]. Broad characterisations of the 
composition of Vipera venoms have yet to be undertaken for most species, although proteomic studies 
of V. raddei and members of the related genus Macrovipera revealed the presence of typical viperid 
toxin families, such as snake venom metalloproteinases, serine proteases, phospholipase A2, C-type 
lectins and disintegrins [27,28]. Specific toxic components have also been isolated and characterised 
from Vipera venoms, including those involved in coagulopathy and neurotoxicity [14,29–31]. 
Importantly, simple protein profiles of different Vipera venoms suggest that there are broad similarities 
in toxin composition [32], whilst evidence that the monospecific equine F(ab')2 V. ammodytes  
―Zagreb antivenom‖ (formally named ―viper venom antiserum, European (equine)‖, Institute of 
Immunology, Zagreb, Croatia) is capable of neutralising the lethal effects of V. berus and V. aspis,  
in addition to V. ammodytes [8,12,13,33], reinforces the suggestion of toxin conservation. 
Here we investigate the immunological cross-reactivity and pre-clinical neutralisation of a variety 
of European vipers with the monospecific V. berus antivenom ViperaTAb
®
. We first assess the 
immunological cross-reactivity of ViperaTAb
®
 antibodies to a range of European viper venoms, using 
ELISA and immunoblotting. We next use a murine in vivo pre-clinical assay, which is the  
gold-standard for predicting antivenom efficacy, to test the neutralising potency of ViperaTAb
®
 
against four representative Vipera venoms (V. berus, V. ammodytes, V. aspis and V. latastei). Finally, 
we assess the resulting cross-reactivity data generated using ViperaTAb
®
 with results gained in these 
assays using the historically well-used Zagreb antivenom as a comparator. 
2. Results and Discussion 
2.1. Immunological Cross-Reactivity Using ELISA 
We first assessed the ability of the monospecific V. berus antivenom ViperaTAb
®
 and the 
monospecific V. ammodytes Zagreb antivenom to recognise and bind to the toxins present in a range of 
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European viper venoms. We used the ELISA technique to quantify the relative binding capacity of 
each antivenom to the venom from each of the following species: V. aspis (France), V. ammodytes 
(Croatia), V. berus (Russia), V. latastei (Spain), V. ursinii (Russia), M. lebetina (Azerbaijan) and  
M. xanthina (Turkey). 
Both antivenoms were found to recognise all of the test European viper venoms screened, albeit to 
varying extents (Figure 1). ViperaTAb
®
 displayed high levels of binding (indicated by the lowest 50% 
binding values) to the venoms of V. latastei, V. ammodytes, V. aspis and V. ursinii, with the binding 
levels detected comparable to that of the venom used during antivenom production (V. berus)  
(Figure 1). These results suggest that the antibodies present in ViperaTAb
®
 antivenom are capable of 
extensive recognition and cross-reactivity with the toxic components present in the venom of other 
European viper species. 
Figure 1. In vitro ELISA cross-reactivity of ViperaTAb
®
 and Zagreb antivenoms to a 
variety of European viper venoms. The 50% binding value represents the amount of 
antivenom (in ng) required to bind half of the test venom on the microtitre plate in the 
ELISA experiment. Thus, the lower the 50% value, the greater the binding capacity of the 
antivenom. Bars for the venoms used to raise the antibodies present in each antivenom are 
highlighted by bold borders (V. berus for ViperaTAb
®
; V. ammodytes for Zagreb).  
Error bars represent standard deviation. 
 
A greater extent of variation in cross-reactivity was observed with the Zagreb product, although of 
the venoms described, only that from V. berus was found to cross-react poorly. The venoms of  
V. latastei and V. ursinii bound at a comparable level to that of the venom used for immunisation  
(V. ammodytes) (Figure 1). Note that the results obtained for the two antivenoms are not directly 
comparable to each other, as different secondary antibody preparations (anti-sheep antibodies for 
ViperaTAb
®
 and anti-horse antibodies for Zagreb) were required to quantify the level of  
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venom-antibody binding. Nonetheless, venom from M. xanthina and M. lebetina cross-reacted with 
both antivenoms to a much lower extent than observed with the venoms from the different Vipera 
species (Figure 1), suggesting that substantial inter-generic differences in toxin composition may exist 
between these different genera of European vipers. However, we cannot exclude the possibility that the 
different venoms tested may vary in their ability to bind to the ELISA plates used, and that this 
confounding factor could potentially explain some of the variation in venom-antivenom binding noted, 
particularly when relating to the results obtained from the non-Vipera species. 
2.2. Immunological Cross-Reactivity Using Immunoblotting 
We next visualised venom-protein antibody-binding by using immunoblotting experiments with the 
venoms of four representative Western European vipers (V. aspis, V. ammodytes, V. berus and  
V. latastei) and the two antivenoms. We first characterised the protein profiles of the four venoms by 
one-dimensional SDS-PAGE gel electrophoresis (Figure 2A). The venom composition of the four 
Vipera species exhibit a wide range of molecular weight proteins, from ~10 kDa to ~75 kDa in size. 
Notably, a number of protein bands appear to be conserved in the venom of the four species, although 
there also appears to be some degree of inter-specific variation in toxin composition, with V. aspis 
containing the most complex profile and V. ammodytes the most simple (Figure 2A). 
Figure 2. The protein profiles of four Vipera venoms and their immunological  
cross-reactivity with ViperaTAb
®
 and Zagreb antivenoms. (A) One dimensional  
SDS-PAGE gel of four Vipera venoms stained with Coomassie Blue R-250 and their 
immunological cross-reactivity with (B) the monospecific V. berus antivenom ViperaTAb
®
 
and (C) the monospecific V. ammodytes Zagreb antivenom. 
 
Immunoblotting these separated venom proteins with ViperaTAb
®
 antivenom revealed extensive 
immunological cross-reactivity, with the antibodies recognising the majority of proteins present in the 
gel (Figure 2B). In the case of V. ammodytes and V. latastei, the binding of ViperaTAb
®
 antivenom to 
venom toxins revealed a number of toxin constituents that were not readily apparent in the initial 
protein profiles. However, the intensity of binding to V. aspis venom was notably lower than  
that observed with the other three Vipera species. Control experiments using normal sheep serum 
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(sourced from non-immunised animals) as a positive control and secondary antibodies only as a 
negative control, revealed no evidence of immunological cross-reactivity with venom proteins. 
Immunoblotting with Zagreb antivenom revealed a similar pattern as that observed with 
ViperaTAb
®
, with many of the venom proteins evident in the gel being recognised by the antivenom 
antibodies (Figure 2C). As with ViperaTAb
®
, the intensity of venom-antibody binding was lower for 
V. aspis than the other members of the genus. For the same reasons as described for the ELISA 
experiments, the intensity of antibody binding observed in the immunoblots is not directly comparable 
between the two antivenoms. However, it is readily apparent that considerably more venom proteins 
were recognised by ViperaTAb
®
 than by the Zagreb antivenom (Figure 2B,C) suggesting that  
V. berus venom, which was used during the immunisation process, may contain a more representative 
venom composition for the genus than that of V. ammodytes. 
2.3. In Vivo Neutralisation of Venom Lethality 
Whilst evidence of extensive immunological cross-reactivity appears to be a prerequisite for 
ensuring antivenom efficacy, evidence of antivenom-venom binding does not guarantee that the toxin 
components present in venom will be neutralised in vivo (e.g., [17]). The gold-standard predictor for 
antivenom efficacy is the murine effective dose 50 assay (ED50), which is a World Health Organisation 
approved assay to determine the amount of antivenom required to protect half a mouse population 
from the lethal effects of venom. First we determined the lethal dose 50 (LD50) dose of each venom 
(Figure 3A), before delivering five LD50 doses of venom that had been mixed with varying doses of 
antivenom in to groups of mice to determine: (I) whether the antivenom protects against lethality and 
(II) if so, at what dose. We undertook these experiments using venoms from the four Western 
European vipers analysed in the immunoblotting assays (V. aspis, V. ammodytes, V. berus and  
V. latastei) and both ViperaTAb
®
 and Zagreb antivenoms. 
Figure 3. Relative in vivo potencies of ViperaTAb
®
 and Zagreb antivenoms against 
venoms from four species of the genus Vipera. (A) Lethal dose 50 (LD50) values for each 
of the four Vipera venoms studied; (B) Effective dose 50 (ED50) values detailing the 
relative potency of ViperaTAb
®
 and Zagreb antivenoms. The effective dose is the amount 
of antivenom antibodies required to protect 50% of a population of mice from the lethal 
effects of five LD50 doses of each venom. Error bars represent 95% confidence intervals. 
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Both antivenoms were found to effectively neutralise five times the venom LD50 from V. berus,  
V. ammodytes, V. aspis and V. latastei (Figure 3). These representative venoms cover a broad 
geographical distribution of Vipera snakes, namely north, south-east, west and south-west Europe, 
respectively. Unlike the immunological cross-reactivity data, the in vivo ED50 data provides a direct 
comparison of the efficacy of the two antivenoms. For all four venoms tested, a smaller amount of 
ViperaTAb
®
 antivenom was required to prevent murine lethality, and therefore achieve complete 
protection (Figure 3). This is evident to the greatest extent when neutralising V. aspis and V. berus 
venoms, where eleven and seven times the amount of Zagreb antivenom is required to prevent  
lethality than observed with ViperaTAb
®
, respectively. The effect is, as expected, less dramatic when 
comparing the neutralisation potencies of the two antivenoms against the venom of V. ammodytes,  
as this is the venom immunogen used to manufacture the Zagreb product (Figure 3). However, these 
results indicate that ViperaTAb
®
 is at least as equally effective as the Zagreb product at neutralising 
the venom of V. ammodytes, despite it not being used as an immunogen during antibody production. 
The ED50 values displayed in Figure 3 can be translated into ―protective units‖, which are defined 
as ―the number of LD50 neutralised per mL of antivenom‖ by using the British Pharmacopoeial test 
method. From these calculations, the potency of ViperaTAb
®
 can be compared with the 
Pharmacopoeial minimum standard set for European viper antivenoms (Table 1). Notably, in all cases, 
ViperaTAb
®
 provides potency results that greatly exceed (by at least double) the required minimum set 
for effective European viper antivenoms. 
Table 1. ViperaTAb
®
 in vivo potency results compared to the regulatory  
Pharmacopoeial standards. 
Venom Pharmacopoeial minimum specification ViperaTAb
®
 antivenom 
Vipera berus 50 597 
Vipera ammodytes 100 222 
Vipera aspis 100 690 
Vipera latastei N/A 176 
Data is expressed as ―protective units‖, which are defined as the number of LD50 venom doses neutralised  
per mL of antivenom. N/A, no specification for V. latastei is provided in the Pharmacopoeial guidelines. 
2.4. Discussion 
Both in vitro antivenom binding experiments demonstrate the inherent cross-reactivity of a variety 
of European viper venoms to the two monospecific antivenoms, ViperaTAb
®
 and Zagreb. The ELISA 
assay demonstrates that a wide range of Vipera venoms are recognised by ViperaTAb
®
 with similar 
binding levels to those observed for V. berus, which was used as the immunogen. ViperaTAb
®
 was 
also capable of binding to the venom of non-Vipera species (M. xanthina and M. lebetina), although 
the level of binding observed was reduced when compared to the Vipera species—this same pattern 
was also found with the anti-V. ammodytes Zagreb antivenom. Therefore the effectiveness of both 
ViperaTAb
®
 and Zagreb antivenoms for the treatment of snakebite against non-Vipera species remains 
unclear at this time, but it appears that these antivenoms are likely to be less effective due to reduced 
levels of antibody-venom binding (Figure 1). 
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The immunoblotting experiments permit the visualisation of the cross-reactivity detected by 
ELISA. Notably, both antivenoms recognise a broad molecular weight range of venom components 
present in the venoms of the four Vipera species, thereby validating the results produced by ELISA. 
The only notable exceptions are (I) that the decrease in binding by the Zagreb antivenom to V. berus 
venom observed in the ELISA experiment (Figure 1) does not appear to be apparent in the 
immunoblot, as the intensity and range of venom protein binding is comparable to the other venoms 
and the toxin components found in the SDS-PAGE gel (Figure 2), and (II) evidence that ViperaTAb
®
 
does not appear to bind to V. aspis venom proteins with the same intensity as to the other venoms in 
the immunoblot (Figure 2), despite comparable binding levels observed by ELISA (Figure 1). 
In contrast to simply providing an indication of whether antibodies recognise and bind to venom 
components, the in vivo pre-clinical ED50 assay provides the most robust evidence (outside of clinical use 
in humans) of antivenom efficacy, by assessing neutralisation of venom-induced mortality in an animal 
model. Notably, our results suggest that ViperaTAb
®
 is likely to be highly efficacious for the treatment 
of snake envenoming by a number of Vipera species, in addition to V. berus (Figure 3, Table 1). Since 
ED50 assays are specified as efficacy release criteria for European antivenoms, the results presented 
here may be used to justify the potential use of ViperaTAb
®
 in clinical trials to treat human 
envenomings by V. aspis, V. latastei and V. ammodytes. The extent of pre-clinical neutralisation well 
exceeded the minimum potency levels defined by Pharmacopoeial guidelines in all cases, and the  
pre-clinical efficacy observed for V. berus, which is comparable to the other three species, has already 
been demonstrated to translate in to clinical efficacy through the decades of successful use of 
ViperaTAb
®
 to treat human patients in Scandinavia [5,21]. 
The results are perhaps more pertinent when comparing the ED50 potencies of ViperaTAb
®
 with the 
Zagreb antivenom. The Zagreb product has been successfully used to treat systemic envenoming by bites 
by V. ammodytes, V. aspis and V. berus in Europe for many years [8,12,13,33]. However, the pre-clinical 
data presented here suggests that ViperaTAb
®
 outperforms the Zagreb antivenom by preventing lethality 
induced by V. berus, V. aspis and V. latastei venom at much lower doses, whilst comparable results were 
observed with V. ammodytes venom. Despite the absence of pre-clinical data for V. ursinii, the results of 
the immunological cross-reactivity study suggest that ViperaTAb
®
 may also have clinical potential for the 
treatment of bites by this species, although ED50 assays will be required to rigorously test this hypothesis. 
The differences in pre-clinical potency observed here between the two antivenoms may in part 
reflect the fact that ViperaTab
®
 is an affinity-purified antivenom, and therefore, milligram to 
milligram, contains a higher number of antibodies specific to Vipera venom proteins than that of the 
non-purified Zagreb product. Ultimately, we therefore conclude that the highly efficacious  
anti-V. berus antivenom ViperaTAb
®
 may also be an effective treatment for snakebite caused by a 
number of different Vipera species found across Europe. 
3. Experimental Section 
3.1. Materials 
Venoms used in this study were purchased from Latoxan, Valence, France. ViperaTAb
®
 antivenom 
was provided by MicroPharm Limited, Carmarthenshire, UK and consists of 25 mg/mL of ovine  
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affinity-purified Fab antibodies specific to the venom of V. berus. Zagreb antivenom was purchased 
from the Institute of Immunology, Zagreb, Croatia and consists of ~100 mg/mL of equine of total 
F(ab')2 antibodies from horses that had been immunised with the venom of V. ammodytes. 
3.2. ELISA 
Ninety-six well microtitre plates were coated with each venom dissolved in coating buffer  
(0.2 µg/well; sodium bicarbonate buffer 0.1 M, pH 9.6 containing 0.1% thiomerosal; 2 h at 37 °C). 
Coated plates were washed three times with washing buffer (300 µL; sodium phosphate 10 mm, 
sodium chloride 0.8%, potassium chloride 0.02%, thiomerosal 0.01% and Tween 20, 0.1%, pH 7.4) to 
remove unbound venom, and then blocked by incubation with the same buffer for 1h at 37 °C. One 
hundred microlitre doubling dilutions of the antivenoms (or a non-immune sheep or horse IgG control 
dissolved in washing buffer) were incubated with the venom for 1 h at 37 °C, before washing as 
before. Bound antibodies were visualised by adding commercially sourced (Sigma-Aldrich, St. Louis, 
MO, USA) secondary antibodies (donkey anti-sheep for ViperaTAb
®
 experiments; sheep anti-horse for 
Zagreb experiments; both coupled to horseradish peroxidase and diluted 1:500 in washing buffer,  
100 µL/well) and incubated for 1 h at 37 °C. After washing a third time, substrate solution was added 
(100 µL/well of o-phenylenediamine, 0.01%, dissolved in sodium citrate buffer, 0.07 M, pH 5.0 
containing H2O2 20 µL/100 mL of a 30% v/v solution) and the reaction stopped after 10 min with the 
addition of sulphuric acid (3 M, 50 µL/well). The optical density of the solution was read at 492 nm 
using an automatic 96 well ELISA plate reader. The amount of antivenom sufficient to bind 50% of 
the venom was calculated from a graph of optical density plotted against antivenom concentration. 
3.3. SDS-PAGE and Immunoblotting 
Venoms from the four Western European Vipera species (V. ammodytes, V. aspis, V. berus and  
V. latastei) were reconstituted to 1 mg/mL in reduced protein loading buffer containing  
2-mecaptoethanol and boiled for 10 min to facilitate protein unfolding. Seven µg of venom, together 
with molecular weight markers (Broad Range Molecular Weight Protein Marker, Promega, 
Southampton, UK), were added to a 15% SDS-PAGE gel and fractionated under 200 volts, as 
previously described [17]. The resultant separated proteins were visualised by staining with Coomassie 
Blue R-250. 
Immunoblotting experiments were carried out in an identical manner except that after the 
completion of protein separation, the gels were electro-blotted onto 0.45 µm nitrocellulose membranes 
at 100 volts, using the manufacturer’s protocols (Bio-Rad, Hemel Hempstead, UK). Following 
confirmation of successful protein transfer by reversible Ponceau S staining, the membranes were 
incubated overnight in blocking buffer (5% non-fat milk in TBST buffer (0.01 M Tris-HCl, pH 8.5, 
0.15 M NaCl and 1% Tween-20)), followed by six washes of TBST over 90 min and incubation 
overnight with either ViperaTAb
®
 or Zagreb antivenoms diluted 1:5000 in blocking buffer.  
The immunoblots were washed again as described above and then incubated for two hours with 
horseradish peroxidise-conjugated donkey anti-sheep secondary antibody (ViperaTAb
®
) or horseradish 
peroxidise-conjugated sheep anti-horse secondary antibody (Zagreb) diluted 1:2000 in TBST.  
The immunoblots were then washed again and venom-protein antivenom-antibody binding visualised 
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with the addition of DAB substrate (50 mg 3,3-diaminobenzidine, 100 mL PBS and 0.024% hydrogen 
peroxide; Sigma-Aldrich, St. Louis, MO, USA). 
3.4. In Vivo Venom Neutralisation (ED50) 
The murine ED50 assay determines the amount of antivenom required to protect half a mouse 
population from the lethal effects of a venom. These assays were undertaken as previously  
described [17,26] by intravenously injecting five groups of five male TSW mice (18–20 g) with 
varying doses of each antivenom, which had previously been mixed and incubated at 37 °C with five 
lethal doses (LD50) of the test venom. The potency of the antivenom was calculated from the number 
of mice surviving after 24 h using probit analysis [34]. Venom LD50 doses, the amount of venom 
required to kill 50% of mice, were previously determined by injecting five groups of five mice with 
varying doses of venom and calculating the LD50 from mortality numbers using probit analysis, as 
previously described [17,26]. For ethical reasons, ED50 assays were only undertaken to assess and 
compare the clinical efficacy of ViperaTAb
®
 and Zagreb antivenoms against venom from four 
representative species of European viper (V. berus, V. ammodytes, V. aspis and V. latastei). All animal 
work was undertaken with local ethical approval and with licensed approval from the UK Home Office. 
4. Conclusions 
Immunological experiments revealed that the anti-V. berus antivenom, ViperaTAb
®
, exhibits 
substantial cross-reactivity with the venoms of other Vipera snake species. Notably, ViperaTAb
®
 
neutralised the lethality induced by V. berus, V. aspis, V. ammodytes and V. latastei venoms in vivo 
and at much higher levels than those outlined by regulatory pharmacopoeial guidelines.  
When compared with the existing, widely used, anti-V. ammodytes ―Zagreb‖ antivenom, ViperaTAb 
performed favourably, with venom neutralisation found to be superior (V. berus, V. aspis and  
V. latastei), or as equally effective (V. ammodytes). Our results suggest that, in addition to V. berus, 
ViperaTAb
®
 shows clinical promise for treating snakebite by a number of other European vipers found 
throughout the continent. 
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